Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of “Moderate Buy” by Brokerages
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price objective among analysts that […]
More Stories
US Navy Directed to Prepare for War With China by 2027
By Andrew Thornebrooke The U.S. Navy on Sept. 19 released a new strategic document centered on countering communist China’s aggression...
America at a Crossroads: The Battle for Sovereignty in the Face of Growing Global Pressures
By Stephen Zogopoulos, USNN World News As the United States grapples with domestic challenges like inflation, rising crime rates, and...
How College Students and Young Adults Can Manage Anxiety
By Mary West College life and the transition into adulthood can be a challenging part of the journey to independence....
Journey of a Security Council resolution
How does a Security Council resolution get adopted? https://ift.tt/QNG8wgt
Iran-Backed Forces in Iraq Claim Missile, Drone Attacks on Israel
By Melanie Sun The Iran-backed Islamic Resistance in Iraq (ISI) claimed responsibility on Sunday for launching cruise missiles and drones...
An Overview of Significant Events on Road to Election and Beyond
By Stacy Robinson We’ve entered the final phase of the 2024 election cycle, which has been marked by twists and...